
Shares of drugmaker Eli Lilly LLY.N marginally down at $761.86 in premarket
Berenberg downgrades stock rating to "hold" from "buy"; slashes PT to $830 from $970
Brokerage says with LLY now the market leader in obesity, consensus expectations for both its marketed and pipeline assets are already elevated, but sees limited upside potential from the current level
On Tuesday, full results from a 72-week trial showed that LLY's experimental GLP-1 pill helped patients lose around 12% of their body weight, with weight-loss plateauing for most participants over time
"We expect Lilly to remain in the obesity driving seat, we also conclude the obesity market upgrade cycle has plateaued, and consensus expectations for Lilly's franchise are high" - Berenberg
Stock rated "buy" on average; median PT is $875.5, as per data compiled by LSEG
As of last close, LLY is down ~1% this year